دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI
FrédéricBouissetMDa?EdouardGerbaudMD, PhDb?VincentBataillePhDacPierreCosteMD, PhDbEtiennePuymiratMD, PhDdLoicBelleMD, PhDeClémentDelmasMDaGuillaumeCaylaMD, PhDfPascalMotreffMD, PhDgGillesLemesleMD, PhDhNadiaAissaouiMD, PhDiDidierBlanchardMDjFrançoisSchieleMD, PhDkTabassomeSimonMD, PhDlNicolasDanchinMD, PhDdJeanFerrièresMD, PhDaFAST-MI Investigators
doi : 10.1016/j.jacc.2021.07.039
Volume 78, Issue 13, 28 September 2021, Pages 1291-1305
The optimal management of patients with ST-segment elevation myocardial infarction (STEMI) presenting late—>12 hours following symptom onset—is still under debate.
Primary PCI, Late Presenting STEMI, and the Limits of Time?
AdnanKastratiMDabJ.J.CoughlanMB, BChaGjinNdrepepaMDa
doi : 10.1016/j.jacc.2021.08.001
Volume 78, Issue 13, 28 September 2021, Pages 1306-1308
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams
Alexander I.PapolosMDaBenjamin B.KenigsbergMDaDavid D.BergMDbCarlos L.AlviarMDcErinBohulaMD, PhDbJames A.BurkeMD, PhDdAnthony P.CarnicelliMDeSunit-PreetChaudhryMDfStavrosDrakosMD, PhDgDaniel A.GerberMDhJianpingGuoMASbJames M.HorowitzMDcJason N.KatzMDeEllen C.KeeleyMDiThomas S.MetkusMDjJoseNativi-NicolauMDgJeffrey R.SnellMDkShashank S.SinhaMDlWayne J.TymchakMDmSeanVan DiepenMDmDavid A.MorrowMDb?Christopher F.BarnettMDa?on behalf of theCritical Care Cardiology Trials Network Investigators
doi : 10.1016/j.jacc.2021.07.044
Volume 78, Issue 13, 28 September 2021, Pages 1309-1317
Single-center studies suggest that implementation of multidisciplinary cardiogenic shock (CS) teams is associated with improved CS survival.
Cardiogenic Shock Management Should Be a Team Sport?
Perwaiz M.MerajMDaWilliam W.O’NeillMDb
doi : 10.1016/j.jacc.2021.07.041
Volume 78, Issue 13, 28 September 2021, Pages 1318-1320
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
James L.JanuzziJr.MDabcFaiezZannadMD, PhDdStefan D.AnkerMD, PhDeJavedButlerMD, MPHfGerasimosFilippatosMDgStuart J.PocockPhDhJoão PedroFerreiraMDiNaveedSattarMDjSubodhVermaMD, PhDkOlaVedinMD, PhDlJanetSchneeMDmTomokoIwataMScnDanCottonMScmMiltonPackerMDopEMPEROR-Reduced Trial Committees and Investigators
doi : 10.1016/j.jacc.2021.07.046
Volume 78, Issue 13, 28 September 2021, Pages 1321-1332
The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) has not been reported.
NT-proBNP Response to Heart Failure Therapies: An Imperfect Surrogate?
Jonathan W.CunninghamMD, MPHaPeder L.MyhreMD, PhDb
doi : 10.1016/j.jacc.2021.07.045
Volume 78, Issue 13, 28 September 2021, Pages 1333-1336
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
MichaelBöhmMDaStefan D.AnkerMD, PhDbJavedButlerMD, MPH, MBAcGerasimosFilippatosMDdJoão PedroFerreiraMD, PhDeStuart J.PocockPhDfFelixMahfoudMDaMartinaBrueckmannMDghWaheedJamalMDgAnne PernilleOfstadMD, PhDiElkeSchülerDipl.MathjPiotrPonikowskiMDkChristophWannerMDlFaiezZannadMD, PhDeMiltonPackerMDmnEMPEROR-Reduced Trial Committees and Investigators
doi : 10.1016/j.jacc.2021.07.049
Volume 78, Issue 13, 28 September 2021, Pages 1337-1348
Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood pressure (SBP) is not known.
Low Blood Pressure and Managing Drugs in HF: Where Do SGLT2 Inhibitors Stand??
NicolasGirerdMD, PhD
doi : 10.1016/j.jacc.2021.07.050
Volume 78, Issue 13, 28 September 2021, Pages 1349-1351
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review
Marco GiuseppeDel BuonoMDaRocco A.MontoneMD, PhDbMassimilianoCamilliMDaSalvatoreCarbonePhDcdJagatNarulaMD, PhDeCarl J.LavieMDfGiampaoloNiccoliMD, PhDgFilippoCreaMDab
doi : 10.1016/j.jacc.2021.07.042
Volume 78, Issue 13, 28 September 2021, Pages 1352-1371
Coronary microvascular dysfunction (CMD) encompasses several pathogenetic mechanisms involving coronary microcirculation and plays a major role in determining myocardial ischemia in patients with angina without obstructive coronary artery disease, as well as in several other conditions, including obstructive coronary artery disease, nonischemic cardiomyopathies, takotsubo syndrome, and heart failure, especially the phenotype associated with preserved ejection fraction. Unfortunately, despite the identified pathophysiological and prognostic role of CMD in several conditions, to date, there is no specific treatment for CMD. Due to the emerging role of CMD as common denominator in different clinical phenotypes, additional research in this area is warranted to provide personalized treatments in this “garden variety” of patients. The purpose of this review is to describe the pathophysiological mechanisms of CMD and its mechanistic and prognostic role across different cardiovascular diseases. We will also discuss diagnostic modalities and the potential therapeutic strategies resulting from recent clinical studies.
Intracranial Hemorrhage During Dual Antiplatelet Therapy: JACC Review Topic of the Week
Andrew C.T.HaMD, MScabDeepak L.BhattMD, MPHcJames T.RutkaMD, PhDadS. ClaiborneJohnstonMD, PhDeC. DavidMazerMDafSubodhVermaMD, PhDaf
doi : 10.1016/j.jacc.2021.07.048
Volume 78, Issue 13, 28 September 2021, Pages 1372-1384
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor is an established therapy for a broad spectrum of patients with cardiovascular disease. The ischemic benefit of DAPT is partially offset by its increased bleeding risk, with intracranial hemorrhage (ICH) being the most serious complication. Although uncommon (0.2%-0.3% annually), its cumulative burden can be substantial given the number of patients afflicted by cardiovascular disease worldwide. Patients with a history of stroke or transient ischemic attack harbor a particularly high risk for ICH when treated with DAPT. Prediction rules may assist clinicians when weighing the risk/benefit ratio of prescribing DAPT for patients with stroke/transient ischemic attack in the nonacute, ambulatory setting. Currently, there are no reversal agents that can rapidly and effectively reverse the effect of P2Y12 inhibitors in routine practice, although a reversal agent for ticagrelor is under clinical investigation.
A Policy Statement on Cardiovascular Test Substitution and Authorization: Principles of Patient-Centered Noninvasive Testing
Randall C.ThompsonMDaTimothy M.BatemanMDaRonBlanksteinMDbMarcelo F.Di CarliMDbBobakHeydariMD, MPHcJudyHungMDdRaymond Y.KwongMD, MPHbJonathan R.LindnerMDefKoenNiemanMD, PhDgSharmilaDorbalaMD, MPHb
doi : 10.1016/j.jacc.2021.07.043
Volume 78, Issue 13, 28 September 2021, Pages 1385-1389
Durability of Minimally Invasive Coronary Artery Bypass Grafting
Ming HaoGuoMDThin XuanVoMD, MScKyraHorsthuisKenzaRahmouniMDAun-YeongChongMDDavidGlineurMD, PhDMarcRuelMD, MPH
doi : 10.1016/j.jacc.2021.07.040
Volume 78, Issue 13, 28 September 2021, Pages 1390-1391
Cardiac Amyloidosis in Patients With Persistent Left Atrial Thrombus
Edward A.El-AmMDAliAhmadMDAngelaDispenzieriMDMarthaGroganMDVuyisile T.NkomoMD, MPH
doi : 10.1016/j.jacc.2021.06.051
Volume 78, Issue 13, 28 September 2021, Page e87
Mind the Denominator: Toward a Better Estimate of Prevalence!
WaelAlqarawiMDF. DanielRamirezMD, MScDavid H.BirnieMBChB, MDMouhannad M.SadekMD
doi : 10.1016/j.jacc.2021.06.052
Volume 78, Issue 13, 28 September 2021, Pages e89-e90
Reply: Effects of Cardiac Amyloidosis and Screening Approach on Left Atrial Thrombus Prevalence in Atrial Fibrillation
AntonyLurieBMScJiaWangMScJeff S.HealeyMD, MScJorge A.WongMD, MPH
doi : 10.1016/j.jacc.2021.07.037
Volume 78, Issue 13, 28 September 2021, Pages e91-e92
Is it Time to Look Deeper?
Christine M.GasperettiMD
doi : 10.1016/j.jacc.2021.07.038
Volume 78, Issue 13, 28 September 2021, Pages e93-e94
